<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Benzodiazepine use disorder</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Benzodiazepine use disorder</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Benzodiazepine use disorder</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tae Woo Park, MD, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Murray B Stein, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1780447160"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Benzodiazepines have anxiolytic, hypnotic, anticonvulsive, and muscle-relaxing properties, which have made them a widely prescribed treatment, primarily for anxiety and insomnia. They also are associated with physical dependence and addiction. Benzodiazepine use disorder can involve misuse of prescribed benzodiazepines and use of diverted benzodiazepines.</p><p>Benzodiazepine use disorder can be a chronic, relapsing disorder and benzodiazepine use has been associated with increased morbidity and mortality in some studies. Misuse of benzodiazepines can be difficult to distinguish from undertreated anxiety or insomnia.</p><p>The epidemiology, pathogenesis, clinical manifestations, course, diagnosis, and treatment of benzodiazepine use disorder are reviewed here. Clinical assessment of substance use disorders is also reviewed separately. Identification and management of prescription drug misuse, including misuse of benzodiazepines, are also reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7807.html" rel="external">"Substance use disorders: Clinical assessment"</a> and  <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">"Prescription drug misuse: Epidemiology, prevention, identification, and management"</a>.)</p><p class="headingAnchor" id="H4245737351"><span class="h1">TERMINOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Controlled substances</strong> – Because of their potential for misuse, addiction, and illicit diversion and sale, opioid analgesics, stimulants, and benzodiazepines and other sedatives/hypnotics are regulated, restricting whether and how they can be prescribed. In the United States, these medications are referred to as "controlled substances" and subject to federal regulations  (<a class="graphic graphic_table graphicRef66064" href="/z/d/graphic/66064.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prescription drug (eg, benzodiazepine) misuse</strong> – Any use of a prescription medication that is outside of the manner and intent for which it was prescribed; this includes overuse, use to get high, diversion (sharing or selling to others), and having multiple prescribers or nonprescribed sources of the medication, or nonprescribed controlled medications. Misuse is a necessary but not sufficient criterion for a substance use disorder. (See  <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">"Prescription drug misuse: Epidemiology, prevention, identification, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonmedical use</strong> – A narrower definition of prescription drug misuse, defined as use of a medication that was not prescribed to the individual or use “only for the feeling or experience it caused” [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prescription drug (eg, benzodiazepine) use disorder</strong> – Misuse of a prescription drug meeting the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria as a substance use disorder [<a href="#rid2">2</a>].</p><p></p><p class="headingAnchor" id="H126442672"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H3797459906"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>Precise data are not available, but estimates suggest a lifetime prevalence of benzodiazepine use disorder of somewhat less than 1 percent. In epidemiologic surveys, benzodiazepines are often categorized with other drugs to create therapeutic drug classes such as sedatives, tranquilizers, and hypnotics; thus, the prevalence of benzodiazepine use disorder specifically in the United States can be difficult to tease out. Nevertheless, the existing data sources roughly describe the scope of the disorder from the late 1990s through the late 2010s:</p><p class="bulletIndent1"><span class="glyph">●</span>The lifetime prevalence of tranquilizer and sedative use disorders (including benzodiazepines, barbiturates, and other older sedative medications) in the United States was estimated to be 1.0 and 1.1 percent respectively [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Past-year prevalence of tranquilizer or sedative use disorder in the United States was estimated to be 0.2 percent [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In persons age 12 years or older in the United States, nearly 2 percent reported past-year illicit use of benzodiazepines. This represents nearly 9 percent of total illicit drug use in this age range [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Substance use disorder treatment admissions for benzodiazepines as the primary substance used have consistently risen and have doubled from 0.5 percent to 1 percent over a 10-year interval (2007 to 2017) [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nationally representative surveys were largely limited to the United States, but as an international point of comparison, in Australia, among Australian individuals 14 years or older, 1.6 percent had past-year nonmedical tranquilizer use [<a href="#rid6">6</a>].</p><p></p><p class="headingAnchor" id="H1840494207"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Several risk factors for benzodiazepine use disorder have been identified [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Longer duration of benzodiazepine use</p><p class="bulletIndent1"><span class="glyph">●</span>Higher benzodiazepine doses</p><p class="bulletIndent1"><span class="glyph">●</span>Lower level of education</p><p></p><p>Misuse of prescribed benzodiazepines, which can contribute to or result from benzodiazepine use disorder, is associated with a [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Greater insomnia severity</p><p class="bulletIndent1"><span class="glyph">●</span>Current antidepressant use</p><p></p><p>High rates of misuse of benzodiazepines have also been found among people who use injection drugs [<a href="#rid9">9</a>] and those receiving <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> maintenance treatment [<a href="#rid10">10,11</a>].</p><p class="headingAnchor" id="H1248452586"><span class="h2">Psychiatric comorbidity</span><span class="headingEndMark"> — </span>Benzodiazepine use disorder has been associated with a broad range of comorbid psychiatric disorders. In a survey of the United States general population, sedative and tranquilizer use disorders were strongly associated with [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Other substance use disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Other prescription drug misuse</p><p class="bulletIndent1"><span class="glyph">●</span>Panic disorder with agoraphobia</p><p class="bulletIndent1"><span class="glyph">●</span>Bipolar I disorder</p><p class="bulletIndent1"><span class="glyph">●</span>Antisocial personality disorder</p><p></p><p class="headingAnchor" id="H2343813870"><span class="h1">PHARMACOLOGY</span></p><p class="headingAnchor" id="H476268142"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span>Benzodiazepines bind to gamma-aminobutyric acid type A (GABA<sub>A</sub>) receptors, which are responsible for most of the inhibitory neurotransmission in the central nervous system and a major target of alcohol, barbiturates, muscle relaxants, and other medications with sedative effects. GABA<sub>A</sub> receptors are ligand-gated chloride ion channels. When gamma-aminobutyric acid (GABA) binds to these receptors, it increases the amount of chloride current generated by the receptor. Benzodiazepines augment GABA’s inhibitory effect by increasing the frequency of channel openings [<a href="#rid12">12</a>]. This inhibitory effect leads to the anxiolytic, hypnotic, anticonvulsive, and muscle-relaxing properties of benzodiazepines.</p><p class="headingAnchor" id="H3426975380"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Benzodiazepines can be categorized into short (15 to 30 minutes), intermediate (30 to 60 minutes), and long-acting agents (one hour or longer). There are at least three determinants of the speed of action of benzodiazepines: half-life, rate of absorption, and lipophilicity. Half-life is determined by how the drug is metabolized and whether it has any active metabolites. A table  (<a class="graphic graphic_table graphicRef65653" href="/z/d/graphic/65653.html" rel="external">table 2</a>) provides data on the dosing and pharmacology of individual benzodiazepines, including their comparative potency, time to onset, metabolism type, and elimination half-life.</p><p>As an example, <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> has a long half-life because it is oxidized by the liver (a relatively slower process) and is metabolized into <a class="drug drug_general" data-topicid="9726" href="/z/d/drug information/9726.html" rel="external">oxazepam</a>, which is an active anxiolytic.</p><p>Most benzodiazepines are absorbed completely but have differing rates of absorption. <a class="drug drug_general" data-topicid="9286" href="/z/d/drug information/9286.html" rel="external">Clorazepate</a> and <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> are both rapidly absorbed, which leads to more rapid increases in plasma levels of these drugs. The greater the lipophilicity of a benzodiazepine, the quicker it enters the brain and therefore a more rapid anxiolytic effect. Lipophilicity varies by &gt;50-fold among benzodiazepines [<a href="#rid13">13</a>]. Diazepam is an example of a highly lipophilic benzodiazepine and <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> of a less lipophilic drug.</p><p class="headingAnchor" id="H457315067"><span class="h2">Physical dependence</span><span class="headingEndMark"> — </span>Chronic benzodiazepine use can cause physical dependence, as evidenced by the benzodiazepine withdrawal syndrome observed in many people who use benzodiazepines long-term upon cessation of the drug. The exact molecular mechanism for physical dependence from benzodiazepine use is not clear [<a href="#rid14">14</a>].</p><p>Chronic exposure to benzodiazepines causes reduced GABA<sub>A</sub> receptor response, and there are changes to GABA<sub>A</sub> receptor subtype expression with chronic benzodiazepine exposure, which leads to a reduced inhibitory response. There is an increased expression of excitatory glutamatergic receptors upon benzodiazepine withdrawal after chronic exposure, which could underlie the symptoms observed in the benzodiazepine withdrawal syndrome.</p><p class="headingAnchor" id="H3473001662"><span class="h2">Addiction liability</span><span class="headingEndMark"> — </span>In a review of animal and human studies that incorporated both human laboratory self-administration and epidemiological data, the liability to misuse benzodiazepines varied by type [<a href="#rid15">15,16</a>]. Speed of onset appears to play a major role in the addiction liability of different benzodiazepine types. <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">Diazepam</a> and flunitrazepam (widely available in Europe, Mexico, and Colombia, but not in the United States), two benzodiazepines with rapid onset, and <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> appear to have the greatest likelihood for misuse, although several commonly prescribed benzodiazepines, such as <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">alprazolam</a> and <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a>, were not included in these studies.</p><p>In a study that used doctor shopping as a proxy for benzodiazepine misuse, flunitrazepam had the highest potential for misuse, followed by <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a>, <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">alprazolam</a>, and <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a> [<a href="#rid17">17</a>]. Flunitrazepam and diazepam are highly lipophilic and are rapidly absorbed. This causes a more rapid onset of action and may lead to a higher liability for misuse.</p><p class="headingAnchor" id="H4104817786"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of addiction is not fully understood; however, use of all addictive drugs, including benzodiazepines, involves increases in dopamine levels in the mesolimbic dopamine system, the reward system of the brain. The ventral tegmental area, located at the origin of the mesolimbic dopamine system, consists of gamma-aminobutyric acid (GABA) interneurons, and dopamine and glutamate neurons. When benzodiazepines bind gamma-aminobutyric acid type A (GABA<sub>A</sub>) receptors on GABA interneurons, they decrease the release of GABA onto dopamine neurons. This lowers the inhibitory effect of GABA interneurons on dopamine neurons, leading to increased dopamine transmission, a process called disinhibition. Benzodiazepines bind a pocket between the alpha and gamma subunits on GABA<sub>A</sub> receptors, and the alpha-1 subunit isoform is believed to be responsible for addictive behavior [<a href="#rid18">18</a>]. GABA<sub>A</sub> receptors with the alpha-1 subunit are abundant in GABA interneurons in the ventral tegmental area of mice [<a href="#rid19">19</a>].</p><p>Synaptic plasticity, or changes in synaptic strength determined by prior synaptic activity, is thought to underlie learning and memory processes. Addictive drugs can cause long-lasting changes to the reward system. Early in this process, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors move from the interior to the surface of dopamine neurons, which leads to greater susceptibility to be stimulated by the excitatory neurotransmitter glutamate [<a href="#rid20">20</a>]. Because of the AMPA receptor migration, future use of addictive drugs can lead to even greater dopamine transmission. Similar to other addictive drugs, benzodiazepine use in mice also leads to the same AMPA receptor migration and the synaptic plasticity found in other addictive drugs [<a href="#rid19">19,21</a>].</p><p>The majority of genetic risk factors for benzodiazepine misuse or use disorder is believed to be nonsubstance specific and thus shared among different substances. In two twin studies, genetic influences were shared across multiple substances including sedatives, cannabis, and stimulants and not specific to substance [<a href="#rid22">22,23</a>]. Twin studies also suggest that the majority of environmental risk factors for substance use disorders shared between twin pairs, such as family environment, is not specific to substance [<a href="#rid23">23,24</a>].</p><p class="headingAnchor" id="H1535687270"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H2078237824"><span class="h2">Benzodiazepine use disorder</span><span class="headingEndMark"> — </span>Patients with a benzodiazepine use disorder may present with a range of severity. Milder cases may have no signs of benzodiazepine use or aberrant medication-taking behaviors only, while patients with greater severity may present with acute intoxication or benzodiazepine withdrawal.</p><p>Patients with a benzodiazepine use disorder may have symptoms or behaviors related to benzodiazepine use, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Benzodiazepines taken in larger amounts or over a longer period than intended</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent desire or unsuccessful efforts to control benzodiazepine use</p><p class="bulletIndent1"><span class="glyph">●</span>Great deal of time spent obtaining or using benzodiazepines</p><p class="bulletIndent1"><span class="glyph">●</span>Craving to use benzodiazepines</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent benzodiazepine use resulting in failure to fulfill major role obligations</p><p class="bulletIndent1"><span class="glyph">●</span>Continued benzodiazepine use despite persistent interpersonal problems</p><p class="bulletIndent1"><span class="glyph">●</span>Important activities given up or reduced because of benzodiazepine use</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent benzodiazepine use in hazardous situations</p><p class="bulletIndent1"><span class="glyph">●</span>Continued benzodiazepine use despite persistent resulting problems</p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of tolerance or withdrawal from benzodiazepine use</p><p></p><p class="headingAnchor" id="H1778291772"><span class="h2">Withdrawal</span></p><p class="headingAnchor" id="H2224864732"><span class="h3">Timing and course</span><span class="headingEndMark"> — </span>Abrupt or overly rapid discontinuation of benzodiazepines after regular use at a recommended dose most commonly leads to a short period (two to three days) of rebound anxiety and insomnia that can occur as soon as one day after discontinuation, depending on the half-life of the benzodiazepine. Some individuals will experience a broader range of symptoms (listed above) that can last up to two weeks.</p><p class="headingAnchor" id="H2999530278"><span class="h3">Clinical manifestations</span><span class="headingEndMark"> — </span>Typical signs and symptoms of benzodiazepine withdrawal include [<a href="#rid25">25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild (2 to 3 days)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anxiety </p><p class="bulletIndent2"><span class="glyph">•</span>Insomnia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate (2 to 14 days)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sleep disturbance</p><p class="bulletIndent2"><span class="glyph">•</span>Irritability</p><p class="bulletIndent2"><span class="glyph">•</span>Anxiety, panic attacks</p><p class="bulletIndent2"><span class="glyph">•</span>Tremor</p><p class="bulletIndent2"><span class="glyph">•</span>Diaphoresis</p><p class="bulletIndent2"><span class="glyph">•</span>Poor concentration</p><p class="bulletIndent2"><span class="glyph">•</span>Nausea, vomiting</p><p class="bulletIndent2"><span class="glyph">•</span>Weight loss</p><p class="bulletIndent2"><span class="glyph">•</span>Palpitations</p><p class="bulletIndent2"><span class="glyph">•</span>Headache</p><p class="bulletIndent2"><span class="glyph">•</span>Muscle pain and stiffness</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe (2 to 14 days)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Seizure</p><p class="bulletIndent2"><span class="glyph">•</span>Psychosis</p><p></p><p class="headingAnchor" id="H2859073729"><span class="h3">Risk factors</span><span class="headingEndMark"> — </span>Withdrawal seizures may be more likely in patients with a history of [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Brain damage</p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol addiction</p><p class="bulletIndent1"><span class="glyph">●</span>Electroencephalogram abnormalities</p><p></p><p>Factors associated with increased severity of benzodiazepine withdrawal include [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Abrupt discontinuation after regular use</p><p class="bulletIndent1"><span class="glyph">●</span>Longer duration of use prior to discontinuation</p><p class="bulletIndent1"><span class="glyph">●</span>Higher doses</p><p class="bulletIndent1"><span class="glyph">●</span>Shorter half-life</p><p></p><p>Benzodiazepine withdrawal is reviewed further separately. (See  <a class="medical medical_review" href="/z/d/html/314.html" rel="external">"Benzodiazepine poisoning"</a> and  <a class="medical medical_review" href="/z/d/html/141183.html" rel="external">"Benzodiazepine withdrawal"</a>.)</p><p class="headingAnchor" id="H1713390167"><span class="h2">Intoxication</span><span class="headingEndMark"> — </span>Signs of benzodiazepine intoxication include slurred speech, incoordination, unsteady gait, and cognitive impairment (in particular, anterograde amnesia or the inability to create new memories). Benzodiazepine intoxication is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/314.html" rel="external">"Benzodiazepine poisoning"</a>.)</p><p class="headingAnchor" id="H1182246555"><span class="h2">Overdose</span><span class="headingEndMark"> — </span>Signs of benzodiazepine overdose include nystagmus, stupor or coma, and respiratory depression. Signs of benzodiazepine withdrawal include anxiety, autonomic hyperactivity, tremor, insomnia, and nausea or vomiting [<a href="#rid2">2</a>]. More severe benzodiazepine withdrawal may lead to transient hallucinations, generalized tonic-clonic seizures, and delirium. Benzodiazepine overdose is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/314.html" rel="external">"Benzodiazepine poisoning"</a>.)</p><p class="headingAnchor" id="H2751908595"><span class="h1">COURSE</span><span class="headingEndMark"> — </span>Little is known about the natural history of benzodiazepine use disorder; the more severe form is believed to be a chronic, relapsing disorder similar to other substance use disorders.</p><p>A study of 221 Swedish individuals (average age of 43 years old when first hospitalized) interviewed approximately 40 years after hospitalization for primary sedative-hypnotic dependence found that approximately [<a href="#rid28">28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Half were misusing sedative-hypnotics at follow-up</p><p class="bulletIndent1"><span class="glyph">●</span>One-fourth died of an unnatural death</p><p class="bulletIndent1"><span class="glyph">●</span>Eighteen percent died of suicide</p><p></p><p>Longitudinal studies of patients who successfully discontinued benzodiazepine use after long-term use and/or developing physically dependence (not assessed for benzodiazepine use disorder) found:</p><p class="bulletIndent1"><span class="glyph">●</span>After 3 years, 73 percent continued to be abstinent from benzodiazepines [<a href="#rid29">29</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>After 10 years, 59 percent continued to be abstinent [<a href="#rid30">30</a>]</p><p></p><p>Few studies have examined the medical consequences of benzodiazepine use disorder. A study of 384 persons with benzodiazepine use disorder found that their mortality was increased compared with the general population but not compared with those without benzodiazepine use disorder who had similar psychiatric illnesses [<a href="#rid31">31</a>]. Numerous studies of benzodiazepine use have found an increased risk of:</p><p class="bulletIndent1"><span class="glyph">●</span>Falls in older adults [<a href="#rid32">32</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Fractures in older adults [<a href="#rid33">33</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive dysfunction [<a href="#rid34">34</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Overdose death when combined with opioids [<a href="#rid35">35,36</a>]</p><p></p><p>Benzodiazepine use has also been associated with an increased risk of all-cause mortality [<a href="#rid37">37,38</a>], but a 2017 study of a large, population-based cohort did not find an increased risk of all-cause mortality with benzodiazepine initiation [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H1394940447"><span class="h1">ASSESSMENT</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Substance use history</strong> – When assessing a patient for benzodiazepine use disorder, it is important to take a complete substance use history including details of benzodiazepine use, past treatment, and use of other addictive substances.</p><p></p><p class="bulletIndent1">Patients may obtain benzodiazepines by prescription or by illicit means. Those that are receiving benzodiazepines by prescription may be nonadherent to the prescriber’s instructions. It is important to ask patients, regardless of the source of medication, about the amount of benzodiazepines being consumed. Shorter half-life benzodiazepines have been associated with greater benzodiazepine withdrawal severity [<a href="#rid25">25</a>], and longer duration of benzodiazepine use and higher benzodiazepine dose have been associated with greater benzodiazepine use disorder severity and benzodiazepine withdrawal severity [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1">Online prescription monitoring programs in the United States and other countries allow clinicians to identify all prescriptions for a patient of a controlled substance, including benzodiazepines, by all prescribers in a given state or region. When possible, prescribers should (and, in some cases, are required to) query these online databases before further prescription to verify a patient’s reported medication history and to detect undisclosed prescriptions from other clinicians. Prescription monitoring programs are reviewed further separately. (See  <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">"Prescription drug misuse: Epidemiology, prevention, identification, and management"</a>.)</p><p></p><p class="bulletIndent1">Patients should be asked specifically about:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Benzodiazepine type</p><p class="bulletIndent2"><span class="glyph">•</span>Dose</p><p class="bulletIndent2"><span class="glyph">•</span>Average number of tablets consumed daily</p><p class="bulletIndent2"><span class="glyph">•</span>Duration of use</p><p class="bulletIndent2"><span class="glyph">•</span>Date of last use</p><p></p><p class="bulletIndent1">Date of last use and half-life provide information on when withdrawal symptoms may begin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other substance use</strong> – Patients should be assessed for use and disorders associated with alcohol and other drugs, in particular opioids and alcohol [<a href="#rid40">40,41</a>]. Combined use of benzodiazepines with other sedating drugs may increase risk of over-sedation and overdose death. Addiction to benzodiazepines may predispose patients to other substance use disorders. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Current or past substance use disorder treatment</strong> – Treatment for benzodiazepine use disorder and other substances includes medically supervised withdrawal (detoxification), residential rehabilitation treatment, mutual help groups, or outpatient substance use disorder services (eg, counseling or medication for addiction). (See  <a class="medical medical_review" href="/z/d/html/7799.html" rel="external">"Substance use disorders: Determining appropriate level of care for treatment", section on 'Levels of care'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comorbidities</strong> – Patients should be assessed for psychiatric comorbidities including depression, anxiety disorders, and insomnia. Antidepressant use and greater insomnia severity have been found to be risk factors for benzodiazepine use disorder among outpatients using benzodiazepines [<a href="#rid7">7</a>]. Treating depression can reduce anxiety and insomnia [<a href="#rid42">42</a>], which may reduce reliance on benzodiazepines [<a href="#rid43">43</a>]. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1">Because benzodiazepine use has been associated with an increased risk of cognitive dysfunction and Alzheimer disease, it is important to assess for cognitive functioning [<a href="#rid35">35,44</a>].</p><p></p><p class="bulletIndent1">Assessing for medical comorbidities, particularly chronic obstructive pulmonary disease (COPD) and chronic noncancer pain, is important in determining the risks of further benzodiazepine use. Benzodiazepine use in patients with COPD has been associated with an increased risk of mortality in a dose-response fashion [<a href="#rid45">45</a>]. Benzodiazepine use is common among patients who take opioids for chronic pain [<a href="#rid46">46</a>]. Benzodiazepines have a dose-response relationship with an increased risk of overdose death in patients receiving opioid analgesics [<a href="#rid34">34</a>]. While assessing for COPD and chronic pain, patients with these conditions who use benzodiazepines can be educated about the mortality risks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination</strong> – The physical examination of patients with benzodiazepine use disorder may reveal signs of benzodiazepine intoxication or withdrawal. Signs of benzodiazepine intoxication include slurred speech, incoordination, unsteady gait, and cognitive impairment. Signs of benzodiazepine withdrawal include anxiety, autonomic hyperactivity, tremor, insomnia, and nausea or vomiting. (See <a class="local">'Intoxication'</a> above and <a class="local">'Withdrawal'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory evaluation</strong> – Patients assessed for a possible benzodiazepine use disorder can usefully be tested for benzodiazepines using a standard urine drug screen, typically performed by immunoassay. Certain benzodiazepines can be more difficult to detect, due to differences in their metabolic pathways. Screening assays are typically able to detect <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a>, <a class="drug drug_general" data-topicid="9243" href="/z/d/drug information/9243.html" rel="external">chlordiazepoxide</a>, <a class="drug drug_general" data-topicid="9973" href="/z/d/drug information/9973.html" rel="external">temazepam</a>, <a class="drug drug_general" data-topicid="9726" href="/z/d/drug information/9726.html" rel="external">oxazepam</a>, and nordazepam (a metabolite). Newer benzodiazepines such as <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">alprazolam</a>, <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a>, and <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> are often more difficult to detect, producing false negative results [<a href="#rid47">47,48</a>].</p><p></p><p class="bulletIndent1">A standard urine drug screen that tests for other substances, including opioids, cocaine, barbiturates, and amphetamine is also suggested, along with testing for alcohol use with a breathalyzer (alcohol detectable up to six hours after use) and/or a biomarker such as ethyl glucuronide (alcohol detectable up to 80 hours after use).</p><p></p><p class="headingAnchor" id="H1025142367"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3288760860"><span class="h2">Benzodiazepine use disorder</span><span class="headingEndMark"> — </span>Benzodiazepine abuse and dependence were replaced by benzodiazepine use disorder. Although the crosswalk between these disorders is imprecise, benzodiazepine dependence is approximately comparable to benzodiazepine use disorder, moderate to severe subtype, while benzodiazepine abuse is similar to the mild subtype [<a href="#rid49">49</a>].</p><p></p><p>DSM-5-TR diagnostic criteria for benzodiazepine use disorder are [<a href="#rid2">2</a>]:</p><p>“A problematic pattern of sedative, hypnotic, or anxiolytic use leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period:</p><p class="bulletIndent1"><span class="glyph">●</span>1. Sedatives, hypnotics, or anxiolytics are often taken in larger amounts or over a longer period than was intended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>2. A persistent desire or unsuccessful efforts to cut down or control sedative, hypnotic, or anxiolytic use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>3. A great deal of time is spent in activities necessary to obtain the sedative, hypnotic, or anxiolytic; use the sedative, hypnotic, or anxiolytic; or recover from its effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>4. Craving, or a strong desire or urge to use the sedative, hypnotic, or anxiolytic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>5. Recurrent sedative, hypnotic, or anxiolytic use resulting in a failure to fulfill major role obligations at work, school, or home.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>6. Continued sedative, hypnotic, or anxiolytic use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of sedatives, hypnotics, or anxiolytics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>7. Important social, occupational, or recreational activities are given up or reduced because of sedative, hypnotic, or anxiolytic use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>8. Recurrent sedative, hypnotic, or anxiolytic use in situations in which it is physically hazardous.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>9. Continued sedative, hypnotic, or anxiolytic use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the sedative, hypnotic, or anxiolytic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>10. Tolerance.*</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>11. Withdrawal.*</p><p></p><p>*These criteria are not considered to be met for individuals taking sedatives, hypnotics, or anxiolytics under medical supervision.</p><p>Specifiers for the diagnosis include:</p><p class="bulletIndent1"><span class="glyph">●</span>In early remission – After full criteria for sedative, hypnotic, or anxiolytic use disorder were previously met, none of the criteria for sedative, hypnotic, or anxiolytic use disorder have been met for at least three months but for less than 12 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In sustained remission – After full criteria for sedative, hypnotic, or anxiolytic use disorder were previously met, none of the criteria for sedative, hypnotic, or anxiolytic use disorder have been met at any time during a period of 12 months or longer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a controlled environment – If the individual is in an environment where access to sedatives, hypnotics, or anxiolytics is restricted.</p><p></p><p>Specifiers for disorder severity are based on the number of criteria met:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild – Presence of two to three criteria.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate – Presence of four to five criteria.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe – Presence of six or more criteria.”</p><p></p><p class="headingAnchor" id="H1836268824"><span class="h2">Benzodiazepine withdrawal</span><span class="headingEndMark"> — </span>Patients with benzodiazepine use disorder may present in benzodiazepine withdrawal. Because symptoms of benzodiazepine withdrawal are similar to those of alcohol withdrawal or withdrawal from other sedative-hypnotics such as barbiturates, it is important to rule out other substance use disorders.</p><p>DSM-5-TR diagnostic criteria for benzodiazepine withdrawal are [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A. Cessation of (or reduction in) benzodiazepine use that has been prolonged.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>B. Two (or more) of the following, developing within several hours to a few days after the cessation of (or reduction in) benzodiazepine use described in criterion A:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>1. Autonomic hyperactivity (eg, sweating or pulse rate &gt;100)</p><p class="bulletIndent2"><span class="glyph">•</span>2. Hand tremor</p><p class="bulletIndent2"><span class="glyph">•</span>3. Insomnia</p><p class="bulletIndent2"><span class="glyph">•</span>4. Nausea or vomiting</p><p class="bulletIndent2"><span class="glyph">•</span>5. Transient visual, tactile, or auditory hallucinations or illusions</p><p class="bulletIndent2"><span class="glyph">•</span>6. Psychomotor agitation</p><p class="bulletIndent2"><span class="glyph">•</span>7. Anxiety</p><p class="bulletIndent2"><span class="glyph">•</span>8. Grand mal seizures</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>C. The signs or symptoms in criterion B cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>D. The signs or symptoms are not attributable to another medical condition and are not better explained by another mental disorder, including intoxication or withdrawal from another substance.</p><p></p><p class="bulletIndent1">Specify if:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>With perceptual disturbances</strong> – This specifier may be noted when hallucinations with intact reality testing or auditory, visual, or tactile illusions occur in the absence of a delirium.</p><p></p><p class="headingAnchor" id="H3236110667"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Assessing a patient for benzodiazepine use disorder can differ depending on whether a patient is receiving a prescribed benzodiazepine or through illicit means. In patients prescribed benzodiazepines, it is often difficult to distinguish between treatment-seeking behavior in patients with undertreated anxiety or insomnia and behaviors to obtain benzodiazepines for nonmedical use. Assessing for aberrant medication taking behaviors can help with assessing for medication misuse. These behaviors include requests for dose increases, running out of medications early, resisting a change in therapy despite adverse effects of the medication, nonadherence with monitoring (eg, pill counts), and “lost” or “stolen” prescriptions [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">"Prescription drug misuse: Epidemiology, prevention, identification, and management"</a>.)</p><p>Patients with benzodiazepine use disorder may present with symptoms of anxiety and depression; anxiety and mood disorders should be ruled out as possible comorbid diagnoses.</p><p class="headingAnchor" id="H3665649057"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment of benzodiazepine use disorder consists of safely tapering patients off of benzodiazepines and preventing return to use once the medications are fully discontinued [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H3428914156"><span class="h2">Medically supervised taper</span></p><p class="headingAnchor" id="H2302955919"><span class="h3">Inpatient versus outpatient treatment</span><span class="headingEndMark"> — </span>Most patients, even those on relatively high doses of benzodiazepines (eg, 100 mg <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> equivalent), can undergo successful benzodiazepine taper in the outpatient setting [<a href="#rid30">30</a>]. Inpatient treatment may occasionally be warranted if the patient has been unable to successfully taper in the outpatient setting despite several attempts or has complicated medical comorbidities, such as a history of seizures, that should be monitored during the taper.</p><p class="headingAnchor" id="H3750358322"><span class="h3">Taper rate</span><span class="headingEndMark"> — </span>In the outpatient setting, we recommend gradual reduction of the benzodiazepine by 25 to 50 percent every 1 to 2 weeks over a period of 6 to 10 weeks. Within this range, individualization of the taper rate depends on patient capacity to tolerate withdrawal symptoms, as well as the dose and duration of benzodiazepine use. Some patients may require longer tapers but prescribers should set clear and realistic goals for decreases in dose.</p><p>Longer durations of use are associated with a higher likelihood of symptoms during the taper. Subjective benzodiazepine withdrawal symptoms during taper can worsen as the reduced dose reaches 25 percent of the initial dose prior to improving as the dose reaches zero [<a href="#rid52">52,53</a>].</p><p>There are limited data on the rate of inpatient benzodiazepine taper. In one small prospective study, 16 out of 23 patients on a mean dose of 150 mg of <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> equivalent were successfully tapered off benzodiazepines in the inpatient setting [<a href="#rid52">52</a>]. A loading dose of diazepam equal to approximately 40 percent of their reported daily dose was followed by a taper of 10 percent per day. While this is a reasonable rate to taper, it should be noted that these patients were not followed up after discharge. For inpatient taper, we suggest that the taper be completed prior to discharge to prevent return to use related to withdrawal symptoms. (See <a class="local">'Benzodiazepine withdrawal'</a> above and <a class="local">'Monitoring and symptom management'</a> below.)</p><p>Clinicians should clearly convey the plan and schedule for tapering to the patient. (See  <a class="medical medical_review" href="/z/d/html/314.html" rel="external">"Benzodiazepine poisoning"</a> and  <a class="medical medical_review" href="/z/d/html/141183.html" rel="external">"Benzodiazepine withdrawal"</a>.)</p><p class="headingAnchor" id="H1539086557"><span class="h3">Choice of benzodiazepine for taper</span><span class="headingEndMark"> — </span>Options include directly tapering the benzodiazepine that the patient is already taking or switching the patient to a long-acting agent to complete the taper. Our approach is to switch patients who are using a single short-acting benzodiazepine to a long-acting benzodiazepine, typically <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> or <a class="drug drug_general" data-topicid="9243" href="/z/d/drug information/9243.html" rel="external">chlordiazepoxide</a>, at an equivalent dose. For those who are on several benzodiazepines, we add up the total daily dose and switch to a single long-acting agent at that equivalent dose. Dosing equivalencies are listed in the table  (<a class="graphic graphic_table graphicRef65653" href="/z/d/graphic/65653.html" rel="external">table 2</a>).</p><p>There is no direct evidence that long-acting benzodiazepines perform better than short-acting benzodiazepines in a taper. However, short-acting benzodiazepines are associated with higher dropout rates from benzodiazepine discontinuation studies, worse “rebound” anxiety (eg, return of underlying anxiety symptoms after benzodiazepine discontinuation), and more severe withdrawal symptoms compared with long-acting benzodiazepines [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H2703583065"><span class="h4">Other medication options</span><span class="headingEndMark"> — </span>Several other agents have been evaluated to taper patients off benzodiazepines, but we do not routinely use them.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">Flumazenil</a>, a benzodiazepine receptor antagonist/partial agonist, has shown early promise in limiting acute withdrawal symptoms and long-term sequelae of benzodiazepine withdrawal in benzodiazepine use disorder; however, further studies on dose, duration of infusion, and safety are needed [<a href="#rid54">54-56</a>]. As an intravenous medication, its use is also limited to the inpatient setting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">Phenobarbital</a> taper has historically been used for medically supervised benzodiazepine taper. While it appears to be effective, we do not recommend its use due to safety concerns, such as a narrow therapeutic index, and limited supporting data [<a href="#rid57">57</a>].</p><p></p><p>Adjunctive therapies (eg, antidepressants and mood stabilizers) have also been evaluated in combination with benzodiazepines during the taper but have a limited role in the absence of specific comorbidities. Meta-analyses are inconclusive regarding the effect of such adjunctive pharmacologic interventions on the success of medically supervised taper or on the frequency of withdrawal symptoms; overall, the quality of evidence for these interventions is low [<a href="#rid58">58,59</a>]. Populations studied in trials were heterogenous, and very few included only patients with benzodiazepine use disorder diagnosis.</p><p class="headingAnchor" id="H2144921005"><span class="h3">Monitoring and symptom management</span><span class="headingEndMark"> — </span>We recommend weekly sessions to monitor patients who are being tapered off of benzodiazepines in the outpatient setting. If patients cannot meet that frequently, we still limit prescriptions for the taper to a week supply to minimize potential overuse.</p><p>If physical symptoms such as anxiety, concentration difficulties, appetite changes, palpitations, restlessness, headache, tremor, or sweat on palms are noted (see <a class="local">'Withdrawal'</a> above), we favor returning to the dose prior to the most recent reduction and slowing down the rate of taper. As an example, if reducing <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> from 20 mg daily to 10 mg daily precipitates tachycardia and diaphoresis, we suggest increasing back to 20 mg daily and lowering to 15 mg instead of 10 mg the next week.</p><p>In inpatient settings, monitoring symptoms using a standardized scale such as the Clinical Institute Withdrawal Assessment-Benzodiazepines is recommended. In this case, a tapering dose can be adjusted or augmented according to a scheduled assessments of score.</p><p class="headingAnchor" id="H2686383782"><span class="h3">Managing comorbidities</span><span class="headingEndMark"> — </span>There is limited evidence that treating comorbidities can improve outcomes of benzodiazepine taper. Use of antidepressants and mood stabilizers has been described for commonly occurring symptoms such as mood instability, anxiety, and insomnia, though further studies are needed [<a href="#rid60">60-62</a>]. Further, evaluation and treatment of symptoms that the patient may have been self-treating with benzodiazepines is prudent to help prevent return to benzodiazepine use.</p><p class="headingAnchor" id="H4219451387"><span class="h4">Depression or anxiety</span><span class="headingEndMark"> — </span>For patients with pre-existing depression or anxiety, we recommend ongoing treatment and close monitoring of comorbid symptoms during medically supervised taper of benzodiazepines. Worsening depression or anxiety may affect the patient’s ability to tolerate symptoms of withdrawal and may lead to early termination of planned taper and escalation of use of benzodiazepines. Management of depression and anxiety are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment"</a> and  <a class="medical medical_review" href="/z/d/html/14671.html" rel="external">"Unipolar depression in adults: Treatment with antidepressant combinations"</a> and  <a class="medical medical_review" href="/z/d/html/101879.html" rel="external">"Generalized anxiety disorder in adults: Management"</a> and  <a class="medical medical_review" href="/z/d/html/14623.html" rel="external">"Comorbid anxiety and depression in adults: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H4082390743"><span class="h4">Insomnia</span><span class="headingEndMark"> — </span>We suggest melatonin for treatment of subjective insomnia during benzodiazepine withdrawal. Melatonin has been shown in one small study to facilitate discontinuation of benzodiazepines while maintaining sleep quality during taper of benzodiazepines [<a href="#rid63">63</a>]. Limited evidence has supported the use of <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> on subjective sleep disturbance during withdrawal from long-term benzodiazepine use; however, this must be weighed against misuse potential [<a href="#rid59">59,61,63-66</a>]. (See  <a class="medical medical_review" href="/z/d/html/97867.html" rel="external">"Overview of the treatment of insomnia in adults"</a>.)</p><p class="headingAnchor" id="H1219559592"><span class="h4">Opioid use disorder</span><span class="headingEndMark"> — </span>Benzodiazepine use is widely reported in individuals with opioid use disorder, including those on opioid agonist therapy. In patients with benzodiazepine use disorder who are receiving opioid agonist therapy, we suggest maintaining a stable dose of opioids throughout the benzodiazepine reduction period in order to prevent opioid withdrawal. The partial opioid agonist <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a> may carry a lower risk of respiratory suppression in combination with benzodiazepine than the full agonist <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a> [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management"</a>.)</p><p class="headingAnchor" id="H4130795128"><span class="h2">Psychosocial augmentation</span><span class="headingEndMark"> — </span>We suggest cognitive-behavioral therapy (CBT) for patients undergoing medically supervised taper of benzodiazepines. In a meta-analysis that included nine trials, adding CBT to a benzodiazepine taper resulted in higher rates of benzodiazepine discontinuation compared with taper alone at three-month follow-up (relative rate of effect 1.51, 95% CI 1.15-1.98) [<a href="#rid68">68</a>]. However, the effects were less certain at six months and longer.</p><p>CBT is the best studied psychosocial intervention in this context. Other options include relaxation training and education material, such as self-help books or tailored clinician letters, which have also been shown to improve benzodiazepine discontinuation rates compared with usual care [<a href="#rid59">59,60,66,68-74</a>]. These methods are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16753.html" rel="external">"Substance use disorders: Psychosocial management"</a>.)</p><p class="headingAnchor" id="H1157420887"><span class="h2">Prevention of recurrence</span><span class="headingEndMark"> — </span>For patients who have successfully tapered off benzodiazepines, we continue counseling regarding the risks of benzodiazepine use disorder. We recommend avoiding therapeutic use of benzodiazepines in such patients. For those who do need benzodiazepine treatment for a different indication, we suggest careful evaluation of the indication for treatment, adherence to dosing suggestions, and timely discontinuation of treatment after four to six weeks [<a href="#rid64">64</a>]. Additionally, we favor referral to a mental health professional for those patients with psychiatric comorbidity. (See <a class="local">'Risk factors'</a> above.)</p><p>As above, prevention of recurrent benzodiazepine use disorder mainly consists of avoidance of benzodiazepines and psychosocial support. There are no randomized controlled trials that have specifically tested an intervention aimed at preventing return to use after successful benzodiazepine discontinuation.</p><p class="headingAnchor" id="H1286776324"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114814.html" rel="external">"Society guideline links: Benzodiazepine use disorder and withdrawal"</a>.)</p><p class="headingAnchor" id="H1479031312"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence </strong>– The lifetime prevalence of benzodiazepine use disorder is less than 1 percent. Substance use disorder treatment admissions for benzodiazepines as the primary substance used have consistently risen over the past decade. Benzodiazepine-related treatment admissions, emergency department visits, and overdose deaths have also increased over that time. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benzodiazepine use disorder </strong>– Patients with a benzodiazepine use disorder may present with a range of severity. Milder cases may have no signs of benzodiazepine use or aberrant medication-taking behaviors only, while patients with greater severity may present with acute intoxication or benzodiazepine withdrawal. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Symptoms</strong> – Predominant signs or behaviors of benzodiazepine use disorder include taking larger amounts over a longer period than intended, unsuccessful efforts to control benzodiazepine use, use of benzodiazepines despite persistent resulting problems, and evidence of tolerance or withdrawal from benzodiazepine use. (See <a class="local">'Benzodiazepine use disorder'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intoxication </strong>– Signs of benzodiazepine intoxication include slurred speech, incoordination, unsteady gait, and cognitive impairment (in particular, anterograde amnesia or the inability to create new memories). (See <a class="local">'Intoxication'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Overdose </strong>– Signs of benzodiazepine overdose include nystagmus, stupor or coma, and respiratory depression. (See <a class="local">'Overdose'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Withdrawal</strong> – Signs of benzodiazepine withdrawal include anxiety, autonomic hyperactivity, tremor, insomnia, and nausea or vomiting. More severe benzodiazepine withdrawal may lead to transient hallucinations, generalized tonic-clonic seizures, and delirium. (See <a class="local">'Withdrawal'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Course </strong>– Little is known about the natural history of benzodiazepine use disorder; the more severe form is believed to be a chronic, relapsing disorder similar to other substance use disorders. (See <a class="local">'Course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment </strong>– When assessing a patient for benzodiazepine use disorder, we ask about a history of past substance use or treatment, benzodiazepine type being used, dose, average number of daily tablets consumed, duration of use, date of last use, and use of other substances with potential for misuse or dependence. (See <a class="local">'Assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– Treatment of benzodiazepine use disorder consists of safely tapering patients off of benzodiazepines and preventing return to use once the medications are fully discontinued. Tapering can occur in outpatient or inpatient settings. We suggest using a long-acting benzodiazepine rather than a short-acting benzodiazepine in the medically supervised taper of individuals with benzodiazepine use disorder (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Medically supervised taper'</a> above.)</p><p></p><p class="bulletIndent1">We suggest cognitive-behavioral therapy as adjunctive treatment for medically supervised taper of benzodiazepines in patients with benzodiazepine use disorder (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Psychosocial augmentation'</a> above.)</p><p></p><p class="bulletIndent1">We recommend weekly sessions to monitor patients who are being tapered off of benzodiazepines in the outpatient setting. If patients cannot meet that frequently, we still limit prescriptions for the taper to a week supply to minimize potential overuse. (See <a class="local">'Monitoring and symptom management'</a> above.)</p><p></p><p class="bulletIndent1">Preventing return to use or recurrent disorder consists of avoidance of therapeutic use of benzodiazepines when possible, and psychosocial support. No pharmacotherapy has demonstrated efficacy. (See <a class="local">'Prevention of recurrence'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings, in NSDUH Series H-44, HHS 2012. Rockville, MD 2012.</li><li class="breakAll">American Psychiatric Association, Diagnostic and Statistical Manual of Mental DIsorders, Fifth Edtion, Text Revision (DSM-5-TR). American Psychiatric Association. 2022.</li><li><a class="nounderline abstract_t">Huang B, Dawson DA, Stinson FS, et al. Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: Results of the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2006; 67:1062.</a></li><li class="breakAll">Substance Abuse and Mental Health Services Administration. 2019 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration; Department of Health and Human Services, Rockville, MD 2020.</li><li class="breakAll">Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2017. Admissions to and Discharges from Publicly-Funded Substance Use Treatment. Substance Abuse and Mental Health Services Administration; Department of Health and Human Services, Rockville, MD 2019.</li><li class="breakAll">AIHW 2014. National Drug Strategy Household Survey detailed report: 2013. Drug statistics series no. 28. Cat. no. PHE 183. Canberra: AIHW.</li><li><a class="nounderline abstract_t">Kan CC, Hilberink SR, Breteler MH. Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach. Compr Psychiatry 2004; 45:88.</a></li><li><a class="nounderline abstract_t">Manthey L, Lohbeck M, Giltay EJ, et al. Correlates of benzodiazepine dependence in the Netherlands Study of Depression and Anxiety. Addiction 2012; 107:2173.</a></li><li><a class="nounderline abstract_t">Darke S. Benzodiazepine use among injecting drug users: problems and implications. Addiction 1994; 89:379.</a></li><li><a class="nounderline abstract_t">Gelkopf M, Bleich A, Hayward R, et al. Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: a 1 year prospective study in an Israeli clinic. Drug Alcohol Depend 1999; 55:63.</a></li><li><a class="nounderline abstract_t">Iguchi MY, Handelsman L, Bickel WK, Griffiths RR. Benzodiazepine and sedative use/abuse by methadone maintenance clients. Drug Alcohol Depend 1993; 32:257.</a></li><li><a class="nounderline abstract_t">Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989; 25:213.</a></li><li><a class="nounderline abstract_t">Greenblatt DJ, Arendt RM, Abernethy DR, et al. In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. Br J Anaesth 1983; 55:985.</a></li><li><a class="nounderline abstract_t">Wafford KA. GABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence? Curr Opin Pharmacol 2005; 5:47.</a></li><li><a class="nounderline abstract_t">Griffiths RR, Weerts EM. Benzodiazepine self-administration in humans and laboratory animals--implications for problems of long-term use and abuse. Psychopharmacology (Berl) 1997; 134:1.</a></li><li><a class="nounderline abstract_t">Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 2005; 66 Suppl 9:31.</a></li><li><a class="nounderline abstract_t">Pradel V, Delga C, Rouby F, et al. Assessment of abuse potential of benzodiazepines from a prescription database using 'doctor shopping' as an indicator. CNS Drugs 2010; 24:611.</a></li><li><a class="nounderline abstract_t">Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999; 401:796.</a></li><li><a class="nounderline abstract_t">Tan KR, Brown M, Labouèbe G, et al. Neural bases for addictive properties of benzodiazepines. Nature 2010; 463:769.</a></li><li><a class="nounderline abstract_t">Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009; 10:561.</a></li><li><a class="nounderline abstract_t">Song J, Shen G, Greenfield LJ Jr, Tietz EI. Benzodiazepine withdrawal-induced glutamatergic plasticity involves up-regulation of GluR1-containing alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in Hippocampal CA1 neurons. J Pharmacol Exp Ther 2007; 322:569.</a></li><li><a class="nounderline abstract_t">Kendler KS, Jacobson KC, Prescott CA, Neale MC. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry 2003; 160:687.</a></li><li><a class="nounderline abstract_t">Kendler KS, Ohlsson H, Maes HH, et al. A population-based Swedish Twin and Sibling Study of cannabis, stimulant and sedative abuse in men. Drug Alcohol Depend 2015; 149:49.</a></li><li><a class="nounderline abstract_t">Tsuang MT, Lyons MJ, Meyer JM, et al. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 1998; 55:967.</a></li><li><a class="nounderline abstract_t">Pétursson H. The benzodiazepine withdrawal syndrome. Addiction 1994; 89:1455.</a></li><li><a class="nounderline abstract_t">Fialip J, Aumaitre O, Eschalier A, et al. Benzodiazepine withdrawal seizures: analysis of 48 case reports. Clin Neuropharmacol 1987; 10:538.</a></li><li><a class="nounderline abstract_t">Roy-Byrne PP, Hommer D. Benzodiazepine withdrawal: overview and implications for the treatment of anxiety. Am J Med 1988; 84:1041.</a></li><li><a class="nounderline abstract_t">Allgulander C, Ljungberg L, Fisher LD. Long-term prognosis in addiction on sedative and hypnotic drugs analyzed with the Cox regression model. Acta Psychiatr Scand 1987; 75:521.</a></li><li><a class="nounderline abstract_t">Rickels K, Case WG, Schweizer E, et al. Long-term benzodiazepine users 3 years after participation in a discontinuation program. Am J Psychiatry 1991; 148:757.</a></li><li><a class="nounderline abstract_t">de Gier NA, Gorgels WJ, Lucassen PL, et al. Discontinuation of long-term benzodiazepine use: 10-year follow-up. Fam Pract 2011; 28:253.</a></li><li><a class="nounderline abstract_t">Piesiur-Strehlow B, Strehlow U, Poser W. Mortality of patients dependent on benzodiazepines. Acta Psychiatr Scand 1986; 73:330.</a></li><li><a class="nounderline abstract_t">Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009; 169:1952.</a></li><li><a class="nounderline abstract_t">Xing D, Ma XL, Ma JX, et al. Association between use of benzodiazepines and risk of fractures: a meta-analysis. Osteoporos Int 2014; 25:105.</a></li><li><a class="nounderline abstract_t">Park TW, Saitz R, Ganoczy D, et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ 2015; 350:h2698.</a></li><li><a class="nounderline abstract_t">Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004; 18:37.</a></li><li><a class="nounderline abstract_t">Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ 2017; 356:j760.</a></li><li><a class="nounderline abstract_t">Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open 2012; 2:e000850.</a></li><li><a class="nounderline abstract_t">Weich S, Pearce HL, Croft P, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ 2014; 348:g1996.</a></li><li><a class="nounderline abstract_t">Patorno E, Glynn RJ, Levin R, et al. Benzodiazepines and risk of all cause mortality in adults: cohort study. BMJ 2017; 358:j2941.</a></li><li><a class="nounderline abstract_t">Darke SG, Ross JE, Hall WD. Benzodiazepine use among injecting heroin users. Med J Aust 1995; 162:645.</a></li><li><a class="nounderline abstract_t">Ciraulo DA, Sands BF, Shader RI. Critical review of liability for benzodiazepine abuse among alcoholics. Am J Psychiatry 1988; 145:1501.</a></li><li><a class="nounderline abstract_t">Taylor DJ, Lichstein KL, Durrence HH, et al. Epidemiology of insomnia, depression, and anxiety. Sleep 2005; 28:1457.</a></li><li><a class="nounderline abstract_t">Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 2005; 35:1747.</a></li><li><a class="nounderline abstract_t">Billioti de Gage S, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer's disease: case-control study. BMJ 2014; 349:g5205.</a></li><li><a class="nounderline abstract_t">Ekström MP, Bornefalk-Hermansson A, Abernethy AP, Currow DC. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ 2014; 348:g445.</a></li><li><a class="nounderline abstract_t">Dellemijn PL, Fields HL. Do benzodiazepines have a role in chronic pain management? Pain 1994; 57:137.</a></li><li><a class="nounderline abstract_t">Negrusz A, Bowen AM, Moore CM, et al. Elimination of 7-aminoclonazepam in urine after a single dose of clonazepam. Anal Bioanal Chem 2003; 376:1198.</a></li><li><a class="nounderline abstract_t">West R, Pesce A, West C, et al. Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in pain management population. Pain Physician 2010; 13:71.</a></li><li><a class="nounderline abstract_t">Compton WM, Dawson DA, Goldstein RB, Grant BF. Crosswalk between DSM-IV dependence and DSM-5 substance use disorders for opioids, cannabis, cocaine and alcohol. Drug Alcohol Depend 2013; 132:387.</a></li><li><a class="nounderline abstract_t">Larance B, Degenhardt L, Lintzeris N, et al. Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug Alcohol Rev 2011; 30:236.</a></li><li><a class="nounderline abstract_t">Miller WR. Retire the Concept of "Relapse". Subst Use Misuse 2015; 50:976.</a></li><li><a class="nounderline abstract_t">Harrison M, Busto U, Naranjo CA, et al. Diazepam tapering in detoxification for high-dose benzodiazepine abuse. Clin Pharmacol Ther 1984; 36:527.</a></li><li><a class="nounderline abstract_t">Brenner PM, Wolf B, Rechlin T, et al. Benzodiazepine dependence: detoxification under standardized conditions. Drug Alcohol Depend 1991; 29:195.</a></li><li><a class="nounderline abstract_t">Hood SD, Norman A, Hince DA, et al. Benzodiazepine dependence and its treatment with low dose flumazenil. Br J Clin Pharmacol 2014; 77:285.</a></li><li><a class="nounderline abstract_t">Faccini M, Leone R, Opri S, et al. Slow subcutaneous infusion of flumazenil for the treatment of long-term, high-dose benzodiazepine users: a review of 214 cases. J Psychopharmacol 2016; 30:1047.</a></li><li><a class="nounderline abstract_t">MacDonald T, Gallo AT, Basso-Hulse G, Hulse GK. Outcomes of patients treated with low-dose flumazenil for benzodiazepine detoxification: A description of 26 participants. Drug Alcohol Depend 2022; 237:109517.</a></li><li><a class="nounderline abstract_t">Kawasaki SS, Jacapraro JS, Rastegar DA. Safety and effectiveness of a fixed-dose phenobarbital protocol for inpatient benzodiazepine detoxification. J Subst Abuse Treat 2012; 43:331.</a></li><li><a class="nounderline abstract_t">Baandrup L, Ebdrup BH, Rasmussen JØ, et al. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev 2018; 3:CD011481.</a></li><li><a class="nounderline abstract_t">Parr JM, Kavanagh DJ, Cahill L, et al. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction 2009; 104:13.</a></li><li><a class="nounderline abstract_t">Lader M, Kyriacou A. Withdrawing Benzodiazepines in Patients With Anxiety Disorders. Curr Psychiatry Rep 2016; 18:8.</a></li><li><a class="nounderline abstract_t">Rubio G, Bobes J, Cervera G, et al. Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use. Eur Addict Res 2011; 17:262.</a></li><li><a class="nounderline abstract_t">Welsh JW, Tretyak V, McHugh RK, et al. Review: Adjunctive pharmacologic approaches for benzodiazepine tapers. Drug Alcohol Depend 2018; 189:96.</a></li><li><a class="nounderline abstract_t">Garfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch Intern Med 1999; 159:2456.</a></li><li><a class="nounderline abstract_t">Soyka M. Treatment of Benzodiazepine Dependence. N Engl J Med 2017; 376:1147.</a></li><li><a class="nounderline abstract_t">Rickels K, Schweizer E, Garcia España F, et al. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology (Berl) 1999; 141:1.</a></li><li><a class="nounderline abstract_t">Voshaar RC, Couvée JE, van Balkom AJ, et al. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry 2006; 189:213.</a></li><li><a class="nounderline abstract_t">Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine: interactions and clinical management. Am J Addict 2010; 19:59.</a></li><li><a class="nounderline abstract_t">Darker CD, Sweeney BP, Barry JM, et al. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev 2015; 5:CD009652.</a></li><li><a class="nounderline abstract_t">Gould RL, Coulson MC, Patel N, et al. Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry 2014; 204:98.</a></li><li><a class="nounderline abstract_t">Ten Wolde GB, Dijkstra A, van Empelen P, et al. Long-term effectiveness of computer-generated tailored patient education on benzodiazepines: a randomized controlled trial. Addiction 2008; 103:662.</a></li><li><a class="nounderline abstract_t">Lynch T, Ryan C, Hughes CM, et al. Brief interventions targeting long-term benzodiazepine and Z-drug use in primary care: a systematic review and meta-analysis. Addiction 2020; 115:1618.</a></li><li><a class="nounderline abstract_t">Tannenbaum C, Martin P, Tamblyn R, et al. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med 2014; 174:890.</a></li><li><a class="nounderline abstract_t">Bashir K, King M, Ashworth M. Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines. Br J Gen Pract 1994; 44:408.</a></li><li><a class="nounderline abstract_t">Vicens C, Fiol F, Llobera J, et al. Withdrawal from long-term benzodiazepine use: randomised trial in family practice. Br J Gen Pract 2006; 56:958.</a></li></ol></div><div id="topicVersionRevision">Topic 88407 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings, in NSDUH Series H-44, HHS 2012. Rockville, MD 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : American Psychiatric Association, Diagnostic and Statistical Manual of Mental DIsorders, Fifth Edtion, Text Revision (DSM-5-TR). American Psychiatric Association. 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16889449" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: Results of the National Epidemiologic Survey on Alcohol and Related Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16889449" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: Results of the National Epidemiologic Survey on Alcohol and Related Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16889449" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: Results of the National Epidemiologic Survey on Alcohol and Related Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16889449" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: Results of the National Epidemiologic Survey on Alcohol and Related Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999658" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22703562" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Correlates of benzodiazepine dependence in the Netherlands Study of Depression and Anxiety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8025489" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Benzodiazepine use among injecting drug users: problems and implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10402150" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: a 1 year prospective study in an Israeli clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8102331" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Benzodiazepine and sedative use/abuse by methadone maintenance clients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2471436" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6626413" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15661625" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : GABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9399364" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Benzodiazepine self-administration in humans and laboratory animals--implications for problems of long-term use and abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16336040" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20527997" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Assessment of abuse potential of benzodiazepines from a prescription database using 'doctor shopping' as an indicator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10548105" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20148031" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Neural bases for addictive properties of benzodiazepines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19571793" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The glutamate homeostasis hypothesis of addiction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17510319" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Benzodiazepine withdrawal-induced glutamatergic plasticity involves up-regulation of GluR1-containing alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in Hippocampal CA1 neurons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668357" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25660314" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A population-based Swedish Twin and Sibling Study of cannabis, stimulant and sedative abuse in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9819064" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7841856" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The benzodiazepine withdrawal syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3427560" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Benzodiazepine withdrawal seizures: analysis of 48 case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2897789" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Benzodiazepine withdrawal: overview and implications for the treatment of anxiety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3604738" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term prognosis in addiction on sedative and hypnotic drugs analyzed with the Cox regression model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2035717" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-term benzodiazepine users 3 years after participation in a discontinuation program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21193495" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Discontinuation of long-term benzodiazepine use: 10-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3716850" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mortality of patients dependent on benzodiazepines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19933955" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Meta-analysis of the impact of 9 medication classes on falls in elderly persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24013517" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Association between use of benzodiazepines and risk of fractures: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26063215" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14731058" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cognitive effects of long-term benzodiazepine use: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28292769" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22371848" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hypnotics' association with mortality or cancer: a matched cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24647164" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28684397" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Benzodiazepines and risk of all cause mortality in adults: cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7603376" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Benzodiazepine use among injecting heroin users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2904227" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Critical review of liability for benzodiazepine abuse among alcoholics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16335332" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Epidemiology of insomnia, depression, and anxiety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16202187" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25208536" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Benzodiazepine use and risk of Alzheimer's disease: case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24482539" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8090510" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Do benzodiazepines have a role in chronic pain management?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12845398" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Elimination of 7-aminoclonazepam in urine after a single dose of clonazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20119465" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in pain management population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23642316" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Crosswalk between DSM-IV dependence and DSM-5 substance use disorders for opioids, cannabis, cocaine and alcohol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21545553" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26361904" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Retire the Concept of "Relapse".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6434221" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Diazepam tapering in detoxification for high-dose benzodiazepine abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1686753" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Benzodiazepine dependence: detoxification under standardized conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23126253" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Benzodiazepine dependence and its treatment with low dose flumazenil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27166362" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Slow subcutaneous infusion of flumazenil for the treatment of long-term, high-dose benzodiazepine users: a review of 214 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35688053" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Outcomes of patients treated with low-dose flumazenil for benzodiazepine detoxification: A description of 26 participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22285834" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Safety and effectiveness of a fixed-dose phenobarbital protocol for inpatient benzodiazepine detoxification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29543325" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18983627" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26733324" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Withdrawing Benzodiazepines in Patients With Anxiety Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21701173" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29906718" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Review: Adjunctive pharmacologic approaches for benzodiazepine tapers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10665894" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28328330" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment of Benzodiazepine Dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9952057" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16946355" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Strategies for discontinuing long-term benzodiazepine use: meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20132123" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Benzodiazepines, methadone and buprenorphine: interactions and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26114884" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Psychosocial interventions for benzodiazepine harmful use, abuse or dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24493654" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18339112" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Long-term effectiveness of computer-generated tailored patient education on benzodiazepines: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31985127" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Brief interventions targeting long-term benzodiazepine and Z-drug use in primary care: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24733354" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8790654" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17132385" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Withdrawal from long-term benzodiazepine use: randomised trial in family practice.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
